Literature DB >> 11480524

Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares.

G R Haines1, M P Brown, R R Gronwall, K A Merritt, L K Baltzley.   

Abstract

Pharmacokinetics and distribution of orbifloxacin into body fluids and endometrium was studied in 6 mares after intragastric (IG) administration at a single dose rate of 7.5 mg/kg body weight. Orbifloxacin concentrations were serially measured in serum, synovial fluid, peritoneal fluid, urine, cerebrospinal fluid, and endometrial tissues over 24 hours. Minimum inhibitory concentrations of orbifloxacin were determined for 120 equine pathogens over an 11-month period. The mean peak serum concentration (Cmax) was 2.41+/-0.30 microg/mL at 1.5 hours after administration and decreased to 0.17+/-0.01 microg/mL (Cmin) at 24 hours. The mean elimination half-life (t1/2) was 9.06+/-1.33 hours and area under the serum concentration vs time curve (AUC) was 20.54+/-1.70 mg h/L. Highest mean peritoneal fluid concentration was 2.15+/-0.49 microg/mL at 2 hours. Highest mean synovial fluid concentration was 1.17+/-0.28 microg/mL at 4 hours. Highest mean urine concentration was 536.67+/-244.79 microg/mL at 2 hours. Highest mean endometrial concentration was 0.72+/-0.23 microg/g at 1.5 hours. Mean CSF concentration was 0.46+/-0.55 microg/mL at 3 hours. The minimum inhibitory concentration of orbifloxacin required to inhibit 90% of isolates (MIC90) ranged from < or = 0.12 to > 8.0 microg/mL, with gram-negative organisms being more sensitive than gram-positive organisms. Orbifloxacin was uniformly absorbed in the 6 mares and was well distributed into body fluids and endometrial tissue. At a dosage of 7.5 mg/kg once a day, many gram-negative pathogens, such as Actinobacillus equuli, Escherichia coli, Pasteurella spp., and Salmonella spp. would be expected to be susceptible to orbifloxacin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11480524      PMCID: PMC1189673     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  30 in total

1.  Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone.

Authors:  J E Burkhardt; M A Hill; J J Turek; W W Carlton
Journal:  Vet Pathol       Date:  1992-05       Impact factor: 2.221

2.  Peritonitis in horses: 67 cases (1985-1990).

Authors:  J F Hawkins; K F Bowman; M C Roberts; P Cowen
Journal:  J Am Vet Med Assoc       Date:  1993-07-15       Impact factor: 1.936

3.  Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin.

Authors:  J E Burkhardt; M A Hill; W W Carlton
Journal:  Toxicol Pathol       Date:  1992       Impact factor: 1.902

4.  Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model.

Authors:  M C Sullivan; B W Cooper; C H Nightingale; R Quintiliani; M T Lawlor
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  A retrospective study of 192 horses affected with septic arthritis/tenosynovitis.

Authors:  R K Schneider; L R Bramlage; R M Moore; L M Mecklenburg; C W Kohn; A A Gabel
Journal:  Equine Vet J       Date:  1992-11       Impact factor: 2.888

6.  Antimicrobial susceptibility of bacterial isolates from 233 horses with musculoskeletal infection during 1979-1989.

Authors:  R M Moore; R K Schneider; J Kowalski; L R Bramlage; L M Mecklenburg; C W Kohn
Journal:  Equine Vet J       Date:  1992-11       Impact factor: 2.888

7.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 8.  Quinolone arthropathy--acute toxicity to immature articular cartilage.

Authors:  A W Gough; O B Kasali; R E Sigler; V Baragi
Journal:  Toxicol Pathol       Date:  1992       Impact factor: 1.902

9.  Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.

Authors:  S Takada; M Kato; S Takayama
Journal:  J Toxicol Environ Health       Date:  1994-05

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  4 in total

1.  Pharmacokinetics of difloxacin and its concentration in body fluids and endometrial tissues of mares after repeated intragastric administration.

Authors:  Aric R Adams; Gregory R Haines; Murray P Brown; Ronald Gronwall; Kelly Merritt
Journal:  Can J Vet Res       Date:  2005-07       Impact factor: 1.310

2.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

3.  Disposition kinetics of orbifloxacin in tissues of crucian carp (Carassius auratus) following a single intramuscular administration.

Authors:  Y R Yang; F Yang; N Sun; G Y Wang
Journal:  Iran J Vet Res       Date:  2019       Impact factor: 1.376

4.  Development and validation of a microbiological agar assay for determination of orbifloxacin in pharmaceutical preparations.

Authors:  Edith C L Cazedey; Hérida R N Salgado
Journal:  Pharmaceutics       Date:  2011-08-29       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.